[Polypeptides and antagonists].
Polypeptides are endogenous agents, involved in the regulation of many physiologic functions and the pathogenesis of several diseases. Polypeptide antagonists form a group of new chemical entities which may provide valid therapeutic agents. Some polypeptides (angiotensin, kinins) are released through the action of proteolytic enzymes (renin, kallikreins) and act as hormones or autacoids; others (substance P, neurotensin) are synthetized by nervous cells to serve as neurotransmitters or neuromodulators. The main homeostatic role of the renin-angiotensin system is to uphold high systemic arterial blood pressure. Overproduction of renin and insufficient checking of renin secretion are among the most common causes of arterial hypertension. Several forms of arterial hypertension (neurovascular, idiopathic) benefit from a reduction in renin-angiotensin system activity. This is achieved either through decreasing renin secretion, by inhibiting conversion of angiotensin I into angiotensin II, or through blocking the peripheral actions (at the receptor sites) of angiotensin II. Renin secretion is very significantly reduced by beta-blocking agents (propranolol); conversion of angiotensin I into angiotensin II is inhibited by teprotide, captopril and their derivatives; peripheral actions of angiotensin II are blocked by saralasin. Bradykinin and related agents produce vasodilation, increase vascular permeability and stimulate pain fibers. Kinins thus reproduce the cardinal features of inflammation and are held to be mediators of the inflammatory reaction. The substance P neuropeptide is found in the brain and bowel; it may act as a transmitter of the sensation of pain at the spinal cord and central nervous system sites. Among other effects outside of the brain, substance P is a potent vasodilator and inhibits renin secretion. Neurotensin is a neuropeptide which produces hypothermia, muscular relaxation and analgesia. Outside of the brain, this peptide is involved in the regulation of gastric secretion, intestinal motility and insulin and glucagon secretion. The vasoactive intestinal peptide, found in certain cholinergic nerve endings, is a large peptide which inhibits gastric secretion, intestinal motility and vascular tone.
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D000959:Antihypertensive Agents; D002216:Captopril / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D007249:Inflammation / Q000503:physiopathology; D007610:Kallikreins / Q000037:antagonists & inhibitors / Q000502:physiology; D007705:Kinins / Q000037:antagonists & inhibitors / Q000502:physiology; D009496:Neurotensin / Q000502:physiology; D010455:Peptides / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000187:drug effects; D013373:Substance P / Q000502:physiology; D014660:Vasoactive Intestinal Peptide / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007705:Kinins; D010455:Peptides; D000804:Angiotensin II; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D009496:Neurotensin; D002216:Captopril; D007610:Kallikreins
Polypeptides et antagonistes.